Low-dose selenite treatment enhances the antitumor activity of osimertinib in EGFR-mutant H1975 NSCLC cells and of adagrasib in KRAS-mutant H358 NSCLC cells.540. This evidence concerns the gene KRAS and non-small cell lung carcinoma.